|
|
|
|
|
|
By Business Of Biotech | On this week's Business of Biotech, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Werner explains why a single engineered tRNA therapy has the potential to treat "hundreds, if not thousands," of rare genetic diseases, and how her own child's rare disease diagnosis shaped her career and approach to drug development. Werner also discusses Alltrna's use of AI and machine learning for drug optimization, the company's planned use of basket trials, and more. | |
|
|
|
By Advancing RNA Live | Life Edit Therapeutics’ April Sena and Tune Therapeutics’ Tyler Goodwin delve into where they see limitations in downstream processing technologies impacting our ability to scale-up high-quality mRNA-LNPs for large scale therapeutics. | |
|
|
|
By BioPhorum | Process analytic technology monitoring and control is rapidly progressing. BioPhorum shares new best practices on how to move from concept through life cycle management and/or regulatory approval of the PAT application. | |
|
|
|
|
|
|
|
| Lessons In Scaling Lipids Production And Purification | Article | Curia | The speed at which the pharmaceutical industry is now developing and manufacturing mRNA drug products at large scale is astounding, yet it has highlighted supply chain vulnerabilities to make the required pharmaceutical ingredients such as lipids. |
|
|
|
|
|
.png){kind=logo}
